Strides Pharma Science Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 8,648.46 million compared to INR 7,943.93 million a year ago. Revenue was INR 8,910.46 million compared to INR 8,045.82 million a year ago. Net loss was INR 800.26 million compared to INR 1,216.71 million a year ago. Basic loss per share from continuing operations was INR 8.86 compared to INR 13.55 a year ago. Diluted loss per share from continuing operations was INR 8.86 compared to INR 13.55 a year ago. Basic loss per share was INR 8.86 compared to INR 13.55 a year ago. Diluted loss per share was INR 8.86 compared to INR 13.55 a year ago.
For the nine months, sales was INR 27,020.17 million compared to INR 22,042.32 million a year ago. Revenue was INR 27,652.24 million compared to INR 22,501.63 million a year ago. Net loss was INR 1,930.93 million compared to INR 4,894.3 million a year ago. Basic loss per share from continuing operations was INR 23.52 compared to INR 54.54 a year ago. Diluted loss per share from continuing operations was INR 23.52 compared to INR 54.54 a year ago. Basic loss per share was INR 21.45 compared to INR 54.54 a year ago. Diluted loss per share was INR 21.45 compared to INR 54.54 a year ago.